

ID No.	K2010	
Project Title	Molecular signature of hematopoietic aging	
Principal Investigator	Estelle Duprez (Research Director, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut-Paoli Calmettes (IPC))	
Project Members	<div>IMSUT Host</div> <div>Atsushi Iwama (Prof., IMSUT)</div> <div>Researcher Members</div> <div>Poplineau Mathilde (PhD/Postdoc, CRCM, IPC)</div> <div>Léonard Hérault (PhD Student, CRCM, IPC)</div> <div>Mazuel Adrien (Undergraduate Student, CRCM, IPC)</div> <div>Naoya Takayama (Associate Prof., Ciba Univ.)</div> <div>Shuhei Koide (Postdoc, IMSUT)</div>	
IMSUT Host		
Researcher Members		
Report		
<p>Resistance to treatment is due to the heterogeneity of the tumor which contains a subset of cancer cells that escape treatment and are responsible for the relapse. We took advantage of the PLZF/RARA retinoic acid (RA) resistant acute promyelocytic leukemia (APL) model to catch relapse-initiating cell features and their vulnerabilities. By developing an integrative single-cell multi-omics analysis (scRNA-seq and scATAC-seq), we uncovered transcriptional and chromatin heterogeneity of the PLZF/RARA APL blasts. We highlighted a subset of cells insensitive to RA-induced differentiation with a strong DNA repair signature ("Rep" cluster) and exhibiting a fine-tuned transcriptional network targeting the histone methyltransferase Ezh2. Combining epigenomic profiling with mouse-derived models for Ezh2 catalytic inhibition or total KO, we revealed an independent methyltransferase Ezh2 activity linked to RA resistance. These findings demonstrate the power of single-cell multi-omics integration to highlight paths to sensitize therapy-resistant leukemia cells.</p>		